Pharming B.V.
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Industrial and Commercial Machinery and Equipment, Not Elsewhere Classified), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Pharming B.V.
Live alerts from global media, monitored by Business Radar
2025-03-05 (beursgorilla.nl)
Green light for new CEO Pharming
(ABM FN-Dow Jones) The shareholders of Pharming gave their approval on Tuesday for the appointment of Fabrice Chouraqui as CEO. Chouraqui immediately succeeds Sijmen de Vries. To make a smooth transfer of tasks and responsibilities ...
Read more
2025-03-05 (beursgorilla.nl)
Green light for new CEO Pharming
(ABM FN-Dow Jones) The shareholders of Pharming gave their approval on Tuesday for the appointment of Fabrice Chouraqui as CEO. Chouraqui immediately succeeds Sijmen de Vries. To make a smooth transfer of tasks and responsibilities ...
Read more
2025-01-21 (globenewswire.com)
Pharming Group to convene Extraordinary General Meeting of Shareholders
Leiden, the Netherlands, January 21, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces it will...
Read more
2025-01-21 (globenewswire.com)
Pharming Group to convene Extraordinary General Meeting of Shareholders
Leiden, the Netherlands, January 21, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces it will...
Read more
2024-10-25 (beursgorilla.nl)
CEO: plenty of growth engines for Pharming
(ABM FN-Dow Jones) Pharming has plenty of growth engines and its first asset Ruconest continues to provide cash flow to fund new developments at the company. CEO Sijmen de Vries said this on Thursday in conversation with ABM Financial News. The...
Read more
2024-10-24 (deaandeelhouder.nl)
Sijmen de Vries stops at Pharming
During the third quarter results, Pharming announced that CEO Sijmen de Vries will step down as figurehead and CEO of the company. De Vries is now 65 years old and has been active as CEO of Pharming for 16 years this week. De Vries: "I have informed the Board of Directors that, after 16 years at the helm of Pharming, I
Read more
2024-10-24 (iex.nl)
CEO De Vries stops at Pharming
Sijmen de Vries will step down as CEO at Pharming after sixteen years to make way for a successor. The company announced this on Thursday with the third quarter figures, which showed steady growth.
Read more
2024-10-24 (iex.nl)
CEO De Vries stops at Pharming
Sijmen de Vries will step down as CEO at Pharming after sixteen years to make way for a successor. The company announced this on Thursday with the third quarter figures, which showed steady growth.
Read more
2024-10-24 (welingelichtekringen.nl)
Unilever rises in AEX, Pharming drops after CEO departure
AMSTERDAM (ANP) - Unilever was among the strongest risers in the AEX index on Thursday. The food group managed to sell more products for the fourth quarter in a row, despite further price...
Read more
2024-10-24 (welingelichtekringen.nl)
Unilever rises in AEX, Pharming drops after CEO departure
AMSTERDAM (ANP) - Unilever was among the strongest risers in the AEX index on Thursday. The food group managed to sell more products for the fourth quarter in a row, despite further price...
Read more
2023-11-01 (iex.nl)
TomThumb | IEX.nl
IEX.nl is the investor platform in the Netherlands. Stay up to date with all relevant information about shares and other investment products. Investing - Price - Shares - Discussion.
Read more
2023-03-30 (prnewswire.co.uk)
Pharming to present at the Guggenheim Healthcare Talks - Genomic Medicines and Rare Disease Days
/PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's Chief Executive Officer, Sijmen de Vries,...
Read more